Recent news on Entacapone

Abbott pulls out of developing Orion's Simdax in the USA  -  Apr 26, 2007
Pharma Times (subscription),Once again sales were driven by its Parkinson's disease drug Stalevo (carbidopa, levodopa and entacapone) - sold with partner Novartis - which increased 3%

7 Companies Searching to Cure Parkinson's  -  Apr 25, 2007
Seeking Alpha,Novartis AG (NVS), a very large Swiss pharmaceutical company, has developed Comtan® (entacapone), a medication for the treatment of Parkinson's Disease.

Orion says Abbott, license holder of Simdax, discontinues US ...  -  Apr 25, 2007
Forbes,HELSINKI (Thomson Financial) - Orion said it was informed by its US partner Abbott, the license holder for Simdax, an Orion-originated compound used for

7 Companies Searching to Cure Parkinson's  -  Apr 25, 2007
Seeking Alpha,Novartis AG (NVS), a very large Swiss pharmaceutical company, has developed Comtan® (entacapone), a medication for the treatment of Parkinson's Disease.

Portion of Orion profits may go towards new Simdax study  -  Feb 7, 2007
Pharma Times (subscription),Once again sales were driven by its Parkinson's disease drug Stalevo (carbidopa, levodopa and entacapone) - sold with partner Novartis - which increased

Using a Diary Card to Manage Parkinson's Disease Symptoms  -  Feb 16, 2007
PharmaLive.com (press release),Stalevo contains entacapone that helps to optimize the benefits of levodopa, enabling many people with PD to have more time to perform everyday tasks,

Orion Oyj: Orion group financial review (proforma) 1-12/2006  -  Feb 6, 2007
Kauppalehti (press release),The favourable development was consequence of the increased sales of the proprietary products, especially the entacapone franchise, as well as well managed

Orion Oyj: Bulletin of orion corporation financial statements for ...  -  Feb 6, 2007
Kauppalehti (press release),The research programme for the development of a more efficient COMT inhibitor than entacapone has progressed to clinical Phase 1 at the turn of the year.

Medialink Features: Using a Diary Card to Manage Parkinson's ...  -  Feb 15, 2007
PR Newswire (press release),Gordon's "wearing off" symptoms, Dr. Waheed prescribed a Parkinson's disease medication called Stalevo(R) (carbidopa, levodopa and entacapone).

ORION: Stalevo improves quality of life with Parkinson's disease ...  Oct 31, 2006
...delayed start analysis Earlier treatment with enhanced levodopa therapy (levodopa, DDCI and entacapone) also showed to be beneficial when compared to ... -Kauppalehti (press release), Earlier initiation of enhanced levodopa therapy could provide ...  Oct 31, 2006
Stalevo (levodopa/carbidopa/entacapone) is an enhanced levodopa therapy for the treatment of Parkinson’s disease indicated for those patients experiencing ... -WebWire (press release), New Evidence Demonstrates Use of Stalevo Improves Quality of Life ...  Nov 1, 2006
In addition, new analysis suggests that patients treated earlier with enhanced levodopa therapy including entacapone experienced a sustained improvement in ... -DG News Orion Oyj: Orion group financial review 1-6/2006  Aug 7, 2006
The development was consequence of the increased sales of the proprietary products, especially the entacapone franchise, and the timings of the deliveries, as ... -Kauppalehti

After the Diagnosis: Managing Parkinson’s Disease  Aug 15, 2006
Entacapone is an enzyme inhibitor that increases the amount of levodopa that reaches the brain. A medication called Stalevo combines ... -ITP.net

AZILECT(TM) brings new hope to Canadians living with Parkinson's ...  Aug 22, 2006
...still experiencing motor fluctuations. In LARGO, both AZILECT(TM) and entacapone were measured against placebo. The TEMPO trial ... -Canada NewsWire

PHARMAC, DHBs welcome increased budget for 2006-07  Jul 19, 2006
...“These include medicines such as temozolomide for brain tumours, adalimumab for rheumatoid arthritis and entacapone for Parkinsons disease.�. ... -Scoop.co.nz



Orion Oyj: Orion group interim report 1-3/2006  May 8, 2006
The exceptionally good performance is consequence of the increased sales of the proprietary products, especially the entacapone franchise, and the timings of ... - Kauppalehti

Parkinson Disease Guidelines Aid Diagnosis, Management  May 9, 2006
Strong evidence supports the use of entacapone, a catechol-O-methyltransferase inhibitor, and rasagiline, a monoamine oxidase inhibitor, to reduce off time. ... - Journal of American Medical Association (subscription)

Orion Q1 earnings beat forecasts on better sales, cost management ...  May 8, 2006
Orion said the improvement in profitability was due to the product franchise for Parkinson's disease treatment entacapone, which it markets in partnership with ... - Forbes





Israeli medical expert addresses UK audience  Apr 9, 2006
Both drugs reduced the time each day that patients suffered from impaired movement but while Entacapone must be taken several times a day, Azilect can be taken ... - European Jewish Press

New Guidelines Update Diagnosis and Treatment of Parkinson's ...  Apr 4, 2006
Rajesh Pahwa, MD, noted that there is strong evidence supporting the use of entacapone (Comtan) and rasagiline (Azilect) to reduce "off" time in patients whose ... - Medscape (subscription)

AAN: New Parkinson's Disease Treatment Guidelines Issued  Apr 7, 2006
The guidelines included the use of new drugs, Comtan (entacapone) and Azilect (rasagiline), and indicated that there is a role in treatment for deep brain ... - MedPage Today

New laboratory approach to treat Parkinson’s  Mar 27, 2006
...the brain. Comtan (entacapone), a so-called COMT inhibitor, has the same effect as carbidopa when taken along with levodopa. It ... - LabTechnologist.com

Stock releases  Mar 21, 2006
Board of Directors of Orion Corporation in the outlook for the year provided in the financial statements release in February, the entacapone product purchases ... - Kauppalehti

Orion Q4 pretax beats forecasts on strong pharma ops; sees pharma ...  Feb 9, 2006
Looking ahead, it said it expects Orion Pharma to grow sales in 2006, boosted especially by the sales of the entacapone product franchise. ... - Forbes

Orion more than doubles Q4 pre-tax yr/yr  Feb 9, 2006
..."Orion Pharma is estimated to show higher net sales than in 2005, boosted especially by the sales of the entacapone product franchise," Orion said in a ... - Newsroom Finland,

Orion Oyj: Orion group 2005 financial statements  09 Feb 2006
...in the non- clinical research of Orion Pharma for Parkinson’s Disease, aiming at even better efficacy and longer action than that achieved with entacapone. ... - Kauppalehti

Orion Q4 pretax beats forecasts on strong pharma ops; sees pharma ...  09 Feb 2006
...it said it expects Orion Pharma to grow sales in 2006, boosted especially by the product franchise for Parkinson's disease treatment entacapone, which it ... - Forbes

International Approvals: Tasmar, Amplimexon, IV Remodulin  Jan 17, 2006
The ban was lifted on the basis of data from an international 32-center, double-blind study in 150 patients optimized on levodopa and entacapone who were ... - Medscape (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional